Disc Medicine, Inc. (IRON)
NASDAQ: IRON · Real-Time Price · USD
66.86
-2.84 (-4.07%)
At close: May 15, 2026, 4:00 PM EDT
66.50
-0.36 (-0.54%)
After-hours: May 15, 2026, 5:44 PM EDT
Disc Medicine Employees
Disc Medicine had 154 employees as of March 31, 2026. The number of employees increased by 60 or 63.83% compared to the same quarter last year.
Employees
154
Change
60
Growth
63.83%
Revenue / Employee
n/a
Profits / Employee
-$1,568,851
Market Cap
2.55B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Mar 31, 2026 | 154 | 60 | 63.83% | 154 | 0 |
| Dec 31, 2025 | 155 | 71 | 84.52% | 155 | 0 |
| Sep 30, 2025 | 142 | 60 | 73.17% | 142 | 0 |
| Jun 30, 2025 | 125 | 47 | 60.26% | 125 | 0 |
| Mar 31, 2025 | 94 | 16 | 20.51% | 94 | 0 |
| Dec 31, 2024 | 84 | 10 | 13.51% | 84 | 0 |
| Sep 30, 2024 | 82 | 22 | 36.67% | 82 | 0 |
| Jun 30, 2024 | 78 | 23 | 41.82% | 78 | 0 |
| Mar 31, 2024 | 78 | 27 | 52.94% | 78 | 0 |
| Dec 31, 2023 | 74 | 28 | 60.87% | 74 | 0 |
| Sep 30, 2023 | 60 | 22 | 57.89% | 60 | 0 |
| Jun 30, 2023 | 55 | 17 | 44.74% | 55 | 0 |
| Mar 31, 2023 | 51 | 13 | 34.21% | 51 | 0 |
| Dec 31, 2022 | 46 | - | - | 46 | 0 |
| Jun 30, 2022 | 38 | - | - | 37 | 1 |
Related Stocks
| Company Name | Employees |
|---|---|
| Ultragenyx Pharmaceutical | 1,371 |
| Tarsus Pharmaceuticals | 370 |
| Arcutis Biotherapeutics | 354 |
| Structure Therapeutics | 220 |
| Celldex Therapeutics | 198 |
| Soleno Therapeutics | 182 |
| Immunome | 177 |
| IDEAYA Biosciences | 145 |
IRON News
- 1 day ago - Disc Medicine price target raised to $80 from $75 at Morgan Stanley - TheFly
- 4 days ago - Disc Medicine Announces Multiple Presentations Across Portfolio at the European Hematology Association (EHA) 2026 Congress - GlobeNewsWire
- 5 days ago - Disc Medicine to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 11 days ago - Disc Medicine reports Q1 EPS ($1.65), consensus ($1.73) - TheFly
- 11 days ago - Disc Medicine Reports First Quarter 2026 Financial Results and Provides Business Update - GlobeNewsWire
- 25 days ago - Disc Medicine Announces Oral Presentation of Data from RALLY-MF Phase 2 Trial of DISC-0974 in Patients with Myelofibrosis and Anemia at the American Society of Clinical Oncology (ASCO) Annual Meeting - GlobeNewsWire
- 7 weeks ago - Disc Medicine, Inc. Investigated by the Portnoy Law Firm - GlobeNewsWire
- 7 weeks ago - Disc Medicine completes enrollment in APOLLO trial - TheFly